Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Herceptin, trastuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing IRVING, Texas, March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading innovator ... Biopharmaceuticals, Diagnostics, Oncology Caris Life Sciences, ADAPT Biotargeting System, trastuzumab, Herceptin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event
Research in breast cancer genomics reveals the potential for combining anti-HER2 therapy with anti-androgen agents.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted Therapies
During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: Jean-Bernard Durand, MD Tags: Conference Report Conferences/MBCC Source Type: news

Why Some Breast Cancer Becomes Resistant to Hormone Therapy Why Some Breast Cancer Becomes Resistant to Hormone Therapy
Acquired mutations in HER2 explain some of the resistance to hormone therapy seen in metastatic breast cancer; this unexpected finding offers a way to clinically manage these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Management of Early-Stage HER2-Positive Breast Cancer
During the 2018 Miami Breast Cancer Conference, Dr. Sara Hurvitz discussed current management options for patients with early-stage HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2018 Category: Cancer & Oncology Authors: Sara Hurvitz, MD Tags: Conferences/MBCC News Source Type: news

Area surrounding a tumor impacts how breast cancer cells grow
(Oregon Health& Science University) A research team from Oregon Health& Science University, led by Joe Gray, Ph.D. and Jim Korkola, Ph.D. discover a tumor's 'microenvironment' plays a critical role in how HER2 positive breast cancer responds to treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2018 Category: International Medicine & Public Health Source Type: news

Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer
Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Study: Two drugs prevent heart problems in breast cancer patients
(University of Kentucky) Data presented from a Late-Breaking Clinical Trial at the American College of Cardiology's 67th Annual Scientific Session Data demonstrated the effectiveness of beta blockers or ACE inhibitors to reduce the risk of cardio toxicity for HER2-positive breast cancer patients undergoing chemotherapy (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2018 Category: Cancer & Oncology Source Type: news

Early HER2+ Breast Cancer May Develop an Immunosuppressive Phenotype After Therapy
Some patients with HER2-positive breast cancer may develop an immunosuppressive phenotype based on an increase in regulatory T cells following treatment. (Source: CancerNetwork)
Source: CancerNetwork - March 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Switching on survival signalling to drive drug resistance
(Queen Mary University of London) Researchers at Queen Mary University of London have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2018 Category: Cancer & Oncology Source Type: news

Dual HER2 Blockade/Chemo Improves Outcomes in Older Breast Cancer Patients
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial? Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

' Soft' Chemo Plus Targeted Therapy Works in HER2 Breast Cancer (CME/CE)
(MedPage Today) -- Combo increased PFS in older patients and had an acceptable safety profile (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 9, 2018 Category: OBGYN Source Type: news

Soft chemotherapy is very effective in older patients when added to targeted treatment in an aggressive breast cancer subtype
(European Organisation for Research and Treatment of Cancer) A trial published todayin The Lancet Oncology, shows that, in older patients with HER2 positive metastatic breast cancer (an aggressive breast cancer subtype where the cancer has spread to other parts of the body), a combination of a 'soft' chemotherapy with antiHER2 therapy is highly active and has low toxicity, important in a frail population. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 9, 2018 Category: International Medicine & Public Health Source Type: news

Trastuzumab Biosimilar Equivalent in Early HER2+ Breast CA Tx (CME/CE)
(MedPage Today) -- Ratio of breast pathologic complete response rate 10% higher with SB3 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2018 Category: Hematology Source Type: news

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
Mutations mimicking growth factor–induced proliferation and motility characterize aggressive subtypes of mammary tumors. To unravel currently unknown players in these processes, we performed phosphoproteomic analysis on untransformed mammary epithelial cells (MCF10A) that were stimulated in culture with epidermal growth factor (EGF). We identified ladinin-1 (LAD1), a largely uncharacterized protein to date, as a phosphorylation-regulated mediator of the EGF-to-ERK pathway. Further experiments revealed that LAD1 mediated the proliferation and migration of mammary cells. LAD1 was transcriptionally induced, phosphorylat...
Source: Signal Transduction Knowledge Environment - January 30, 2018 Category: Science Authors: Roth, L., Srivastava, S., Lindzen, M., Sas-Chen, A., Sheffer, M., Lauriola, M., Enuka, Y., Noronha, A., Mancini, M., Lavi, S., Tarcic, G., Pines, G., Nevo, N., Heyman, O., Ziv, T., Rueda, O. M., Gnocchi, D., Pikarski, E., Admon, A., Caldas, C., Yarden, Y. Tags: STKE Research Articles Source Type: news

Two Agents Offer Similar pCR Rates in ETNA Breast Cancer Trial (CME/CE)
(MedPage Today) -- Tumor subtype most significant factor for response among ERBB/HER2-negative patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 15, 2018 Category: Hematology Source Type: news

UC researchers find protein that mediates formation of HER2-driven breast cancer
(University of Cincinnati Academic Health Center) Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2018 Category: Cancer & Oncology Source Type: news

Novartis Kisqali ® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. (Source: World Pharma News)
Source: World Pharma News - January 3, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Trastuzumab: No negative impact on cardiac function
(NRG Oncology) Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 3, 2018 Category: International Medicine & Public Health Source Type: news

Will Immunotherapy Be a PANACEA for Breast Cancer? Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer
Early research finds that ganetespib added to paclitaxel and trastuzumab shows promise for heavily pretreated patients with HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Mylan breast cancer drug approved in Brazil
Mylan NV on Friday said it had received the green light in Brazil for a treatment for breast cancer that it developed with a partner in the country. Biocon LTD (BSE: BIOCON) and Mylan (Nasdaq: MYL) co-developed biosimilar Trastuzumab, which treats overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer. It will be sold in Brazil in Brazil as Zedora by Libbs Farmac eutica. "The approval of Zedora, Brazil's first Trastuzumab… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Triple Therapy Improves PFS in Certain Breast Ca Patients (CME/CE)
(MedPage Today) -- Dual HER2 blockade combined with aromatase inhibitor shows benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 28, 2017 Category: Hematology Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - December 21, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer
Early research finds limited activity with the combination of lapatinib and foretinib for advanced HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer
Does aspirin or ibuprofen reduce risk of HER2+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC
Is the combination of everolimus, trastuzumab, and paclitaxel as safe in Asian patients as it is in the overall population?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: news

Ribociclib Effective in Younger Breast Cancer Patients Too Ribociclib Effective in Younger Breast Cancer Patients Too
In premenopausal women with HR-positive, HER2-negative advanced breast cancer, the CDK4/6 inhibitor plus endocrine therapy dramatically improves progression-free survival compared with endocrine therapy alone.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biological factors don't fully explain racial disparities for breast cancer type
(UNC Lineberger Comprehensive Cancer Center) The biological features of patients' tumors partially explained a racial disparity for women with hormone receptor-positive, HER2-negative breast cancer, but UNC Lineberger Comprehensive Cancer Center researchers said it didn't explain it completely. The preliminary findings were reported at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2017 Category: International Medicine & Public Health Source Type: news

SABCS: Ribociclib Ups PFS in HR + HER2 − Advanced Breast Cancer
Significant improvement in progression - free survival for pre - and perimenopausal women (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 7, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Conference News, Source Type: news

Trastuzumab No Benefit In Low-HER2 Breast Cancer (CME/CE)
(MedPage Today) -- New findings should ditch use of drug for women not clearly HER2-positive (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 6, 2017 Category: Surgery Source Type: news

No Trastuzumab Benefit in HER2-Low Breast Cancer After All No Trastuzumab Benefit in HER2-Low Breast Cancer After All
Despite previous analyses suggesting that adding trastuzumab to adjuvant chemotherapy may benefit patients with low HER2 expression, a new large trial shows no impact on outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ
Malignant tumors reprogram cellular metabolism to support cancer cell proliferation and survival. Although most cancers depend on a high rate of aerobic glycolysis, many cancer cells also display addiction to glutamine. Glutamine transporters and glutaminase activity are critical for glutamine metabolism in tumor cells. We found that the receptor tyrosine kinase EphA2 activated the TEAD family transcriptional coactivators YAP and TAZ (YAP/TAZ), likely in a ligand-independent manner, to promote glutamine metabolism in cells and mouse models of HER2-positive breast cancer. Overexpression of EphA2 induced the nuclear accumula...
Source: Signal Transduction Knowledge Environment - December 5, 2017 Category: Science Authors: Edwards, D. N., Ngwa, V. M., Wang, S., Shiuan, E., Brantley-Sieders, D. M., Kim, L. C., Reynolds, A. B., Chen, J. Tags: STKE Research Articles Source Type: news

FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer
The agency has approved the first biosimilar that corresponds to Herceptin for use in HER2+ breast and metastatic stomach cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Trastuzumab Biosimilar
(MedPage Today) -- Includes HER2-positive breast, stomach cancer (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 1, 2017 Category: Gastroenterology Source Type: news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Ogivri, a biosimilar to the cancer drug Herceptin, is approved for HER2+ breast cancer and metastatic stomach cancers SILVER SPRING, Md., Dec. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Ogiv... Biopharmaceuticals, Oncology, FDA Mylan, Ogivri, trastuzumab-dkst, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 1, 2017 Category: Pharmaceuticals Source Type: news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers
The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer. (Source: World Pharma News)
Source: World Pharma News - December 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

What's Hot at SABCS 2017? What's Hot at SABCS 2017?
Can the duration of adjuvant therapy in breast cancer be reduced? Is trastuzumab effective in HER2-negative tumors? These are among the hot topics that will be discussed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neratinib: Extended Adjuvant Therapy, But When to Prescribe? Neratinib: Extended Adjuvant Therapy, But When to Prescribe?
The ExteNET study led to the approval of neratinib for extended adjuvant treatment of early-stage HER2+ breast cancer. But when should it be prescribed?Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Negligible Benefit Of Nerlynx, A New Breast Cancer Drug, Calls For Caution
The question for patients with early-stage HER2+ breast cancer is if it ’s worth taking a treatment (Nerlynx) that lowers the risk of distant recurrence by less than 2% at 5 years, and which has not yet been studied over the long term. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2017 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Tags: NASDAQ:PBYI VTX:ROG Source Type: news

More than 1,300 women to get breakthrough cancer drug
The treatment – for the aggressive HER2+ form of the disease – extends life for women dying with breast cancer by an average 56 months, 16 months more than the next best treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - November 10, 2017 Category: Consumer Health News Source Type: news

FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio ™ (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - October 13, 2017 Category: Pharmaceuticals Source Type: news